Codestin Search App

Overview

Cancer Immunology, Immunotherapy is providing a timely and open access publication of original discovery and developments in basic and translational research in the field of cancer immunology and immunotherapy.

Editor-in-Chief

Haidong Dong

Societies and partnerships

Journal metrics

Journal Impact Factor: 5.1 (2024)

5-year Journal Impact Factor: 5.4 (2024)

Submission to first decision (median): 3 days

Downloads: 1.5M (2024)

Call for papers

Collection

Natural Killer cell therapy

View the webinar recording based on this Natural Killer Cell Therapy collection.

View all calls for papers

Latest articles

Integrating necroptosis and immune landscapes: a multi-omics-derived NecropImmScore stratifies prognosis and therapy in ovarian cancer
Fangfang Xu
Shufeng Kang
Shaohua Xu
Research Open access 15 October 2025 Article: 340
CAR NK cell production from human cord blood NK progenitor cells is enhanced by stimulation of the IL-15 receptor
Yosuke Kogue
Shunya Ikeda
Naoki Hosen
Brief Report Open access 13 October 2025 Article: 338
Part of 1 collection:

Natural Killer cell therapy
Adjuvant immunotherapy fails to improve survival in ypStage I esophageal cancer after neoadjuvant immunochemotherapy
Yan Huang
Fan Dong
Jianhua Fu
Research Open access 13 October 2025 Article: 337
The single-cell atlas of colorectal cancer reveals cellular heterogeneity and key molecular features of the tumor immune microenvironment
JunHu Li
ZhiQiang Liu
YueNan Huang
Research Open access 10 October 2025 Article: 336
Comprehensive proteomic and pathological profiling identifies PRAS40 as a novel biomarker and mediator of primary immune checkpoint blockade resistance in non-small cell lung cancer
Ning Mao
Cui He
Zhao Yang
Research Open access 10 October 2025 Article: 335

View all articles

Journal updates

Cancer Immunology, Immunotherapy is now fully open access!

We are excited to announce that Cancer Immunology, Immunotherapy has now become a fully open-access (OA) journal as of 5^th January 2024. This means that we will only be publishing articles as Open Access meaning content will be freely available to readers worldwide, enabling the widest possible dissemination and reuse.
Springer Nature Oncology Webinar Series

Sign up for free online attendance.
Learn more about Springer Nature’s oncology titles

Discover the range of academic oncology titles at Springer Nature here.
Announcing new Editor-in-Chief: Dr. Haidong Dong

The journal is pleased to announce Dr. Haidong Dong has been named the new Editor-in-Chief of Cancer Immunology, Immunotherapy, effective January 1, 2020.